Virtus ETF Advisers LLC grew its holdings in shares of Avrobio Inc (NASDAQ:AVRO) by 81.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,695 shares of the company’s stock after acquiring an additional 8,845 shares during the period. Virtus ETF Advisers LLC owned 0.08% of Avrobio worth $320,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of AVRO. BNP Paribas Arbitrage SA acquired a new stake in Avrobio during the 1st quarter worth about $59,000. Rhumbline Advisers acquired a new stake in Avrobio during the 1st quarter worth about $296,000. Bessemer Group Inc. acquired a new stake in Avrobio during the 2nd quarter worth about $336,000. Wells Fargo & Company MN grew its holdings in Avrobio by 160.2% during the 2nd quarter. Wells Fargo & Company MN now owns 24,551 shares of the company’s stock worth $400,000 after acquiring an additional 15,114 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Avrobio by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,039 shares of the company’s stock worth $814,000 after acquiring an additional 4,820 shares during the period. Hedge funds and other institutional investors own 68.55% of the company’s stock.
In other news, Director Bruce Booth bought 810,811 shares of Avrobio stock in a transaction dated Friday, July 19th. The stock was bought at an average cost of $18.50 per share, for a total transaction of $15,000,003.50. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 4.70% of the company’s stock.
Several analysts have recently commented on AVRO shares. Zacks Investment Research upgraded Avrobio from a “sell” rating to a “hold” rating and set a $25.00 target price for the company in a research note on Tuesday, July 23rd. ValuEngine upgraded Avrobio from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Wedbush restated an “outperform” rating and issued a $43.00 target price on shares of Avrobio in a research note on Friday, August 9th. Cowen restated a “buy” rating on shares of Avrobio in a research note on Monday, July 15th. Finally, Mizuho restated a “buy” rating and issued a $28.00 target price on shares of Avrobio in a research note on Sunday, August 11th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Avrobio currently has an average rating of “Buy” and a consensus target price of $29.07.
Shares of AVRO traded down $0.47 during trading hours on Friday, hitting $19.73. The stock had a trading volume of 77,420 shares, compared to its average volume of 179,010. The firm has a 50 day simple moving average of $19.64 and a 200-day simple moving average of $18.20. The firm has a market capitalization of $495.01 million, a P/E ratio of -5.45 and a beta of 2.72. Avrobio Inc has a 1-year low of $11.85 and a 1-year high of $53.70.
Avrobio (NASDAQ:AVRO) last issued its earnings results on Thursday, August 8th. The company reported ($0.67) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.09. On average, research analysts forecast that Avrobio Inc will post -2.48 EPS for the current fiscal year.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Recommended Story: Street Name
Want to see what other hedge funds are holding AVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avrobio Inc (NASDAQ:AVRO).
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.